Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D‐first study

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 9, 2015-09 ,pp. : 819-824

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rapid reduction in BCR‐ABL1 transcript predicts deep molecular response in dasatinib‐treated chronic‐phase chronic myeloid leukaemia patients

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 100, Iss. 1, 2018-01 ,pp. : 27-35

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase‐2 study (NordCML006)

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 3, 2015-03 ,pp. : 243-250

John Wiley & Sons Inc

Access to resources Recommend Favorite

International Reporting Scale of BCR-ABL1 Fusion Transcript in Chronic Myeloid Leukemia: First Report from India

By  

Acta Haematologica, Vol. 127, Iss. 3, 2012-01 ,pp. : 135-142

Karger

Access to resources Recommend Favorite

Case study of primary imatinib resistance and correlation of BCR-ABL multiple mutations in chronic myeloid leukemia

By Iqbal Zafar   Siddiqui Rubina T   Qureshi Javed A   Khalid Ahmad M  

Therapy, Vol. 1, Iss. 2, 2004-11 ,pp. : 249-254

Future Medicine

Access to resources Recommend Favorite